Critical issues of HIV treatment in the era of highly active antiretroviral therapy

Bibliography

• EGGER M, HIRSCHEL B, FRANCIOLI P et al.: Impact of new antiretroviral combination therapies in FIRT infected patients in Switzerland: prospective multicentre study. Br. Med. J. (1997) 315:1194–1199.
   PubMed Web of Science ®Google Scholar
• ••First large observational report on decline of morbidity andmortality outside of randomised trials.
   Google Scholar
• HAMMER SM, SQUIRES KE, HUGHES MD et al.: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N. Engl. J. Med. (1997) 337(11):725–733.
   Google Scholar
• ••Landmark study on double versus triple combinationtherapy demonstrating the potency of HAART.
   Google Scholar
• PALELLA FJ, JR., DELANEY KM, MOORMAN AC et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. (1998) 338(13):853–860. Important epidemiological study.
   Google Scholar
• HO DD: Time to hit HIV, early and hard. N. Engl. J. Med. (1995) 333(7):450–451.
   PubMed Web of Science ®Google Scholar
• MELLORS JW, RINALDO CR, JR., GUPTA P, WHITE RM, TODD JA, KINGSLEY LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science (1996) 272(5265):1167–1170.
   Google Scholar
• ••First study indicating the clinical value of quantifying viralload.
   Google Scholar
• LEDERGERBER B, EGGER M, OPRAVIL M et al.: Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet (1999) 353 (9156):863–868.
   Google Scholar
• ••Comprehensive clinical study on a large patient populationon clinical progression and virological failure on HAART.
   Google Scholar
• LEDERMANN MM, VALDEZ H: Immune restoration with antiretroviral therapies. JAMA (2000) 284 (2):223–288.
   PubMed Web of Science ®Google Scholar
• SENDI PP, BUCHER HC, HARR T et al.: Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 13 (9):1115–1122.
   Google Scholar
• •Large study taking societal perspective into account regarding costs.
   Google Scholar
• ROSENBERG ES, ALTFELD M, POON SH et al.: Immune control of HIV-1 after early treatment of acute infection. Nature (2000) 407 (6803):523–526.
   PubMed Web of Science ®Google Scholar
• ••Pathophysiologically convincing evidence to start therapyextremely early.
   Google Scholar
• CARPENTER CC: Effect of ritonavir on saquinavir metabolism. JAMA (2000) 283 (22):2936–2937.
   PubMed Web of Science ®Google Scholar
• BATTEGAY M, WIRZ M, STEUERWALD MH, EGGER M: Early participation in a HIV cohort study slows disease progression and improves survival. The Swiss HIV Cohort Study. J Intern. Med. (1998) 244:479–487.
   Google Scholar
• KITAHATA MM, KOEPSELL TD, DEYO RA, MAXWELL CL, DODGE WT, WAGNER EH: Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N. Engl. J. Med. (1996) 334 (11):701–706.
   PubMed Web of Science ®Google Scholar
• •Study showing the importance of experienced doctors.
   Google Scholar
• CARR A, SAMARAS K, THORISDOTTIR A, KAUFMANN GR, CHISHOLM DJ, COOPER DA: Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet (1999) 353 (9170):2093–2099.
   PubMed Web of Science ®Google Scholar
• •Important study on metabolic problems during HAART.
   Google Scholar
• PERIARD D, TELENTI A, SUDRE P et al.: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation (1999) 1 0 0 (7) :700–705.
   Google Scholar
• MAX B, SHERER R: Management of the adverse effects of antiretroviral therapy and medication adherence. Clin. Infect. Dis. (2000) 30 (Suppl. 2):S96–116.
   Google Scholar
• BEAN P, PATNAIK M, GRAZIANO FM, AZIZ DC: Therapeutic drug monitoring of antiretroviral agents. Am. Clin. Lab. (2000) 19(4):20–22.
   PubMedGoogle Scholar
• BASSETTI S, BATTEGAY M, FURRER HJ et al.: Why is Highly Active An tir etr ovir al Therapy (HAART) not prescribed or discontinued? J. Acquit'. Immune. Defic. Syndr. Hum. Retrovirol. (1999) 21:114–119.
   PubMed Web of Science ®Google Scholar
• •Study on patients' perspective.
   Google Scholar
• HANSEL A, BUCHER HC, HOESCH R, BATTEGAY M: Durability and reasons for discontinuation of first highly active antiretroviral therapy (HAART) in a cohort of proteinase inhibitor naive HIV-infected patients. J. Acquir. Immune. Defic. Syndr. Hum. Retrovirol. (2001). (In Press).
   Google Scholar
• ERB P, BATTEGAY M, ZIMMERLI W, EGGER M, RICKEN-BACH M AND THE SWISS HIV COHORT STUDY: Effect of antiretroviral therapy on viral load and lymphocyte numbers in an unselected cohort of HIV-infected individuals. Arch. Intern. Med. (2000) 160:1134–1140.
   PubMedGoogle Scholar
• •Long term data on HAART.
   Google Scholar
• WOOD AJJ: HIV-protease inhibitors. N. Engl. J. Med. (1998) 338:1281–1292.
   PubMed Web of Science ®Google Scholar
• KHANNA N, SCHIFFER V, KLIMKAIT T et al.: Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase inhibitor and a protease inhibitor in heavily pretreated HEV-1 infected patients. AIDS (2000) 14:791–799.
   PubMed Web of Science ®Google Scholar
• DEEKS SG, BARBOUR JD, MARTIN JN, SWANSON MS,GRANT RM: Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect. Dis. (2000) 181 (3):946–953.
   PubMed Web of Science ®Google Scholar
• •One of several studies indicating that CD4 T-cell responses are sustained even if HAART fails virologically.
   Google Scholar